Data
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Cognito Therapeutics has revealed data from its OVERTURE feasibility study backing up the ability of its non-invasive Spectris headset to treat Alzheimer’s via the stimulation of gamma oscillations. The company is hoping to launch the device in 2027
Praxis Precision Medicines is planning to shift from a clinical-stage company to a competitive commercial player in CNS, with the potential to launch multiple blockbuster medicines in the near future.
A deep dive into sales expectations for individual pharma products reveals incretin agonists, immunology biologics and new formulations of established blockbusters dominating growth forecasts this year, with Merck & Co., Lilly, AbbVie and Bristol Myers Squibb particularly well positioned in 2026.
Germany’s updated digital healthcare “manifesto” document reflects the need to dovetail with EU’s EHDS and factor in advances in AI, and provide for a new system of primary care. The medtech industry calls for faster assessments of AI-enabled technology and better access to telemonitoring tools.
For In Vivo's 18th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
Thirteen $1bn+ alliances were penned in December, and three exceeded $2bn. In the top alliance by deal value, OTR Therapeutics and Zealand Pharma entered a potential $2.5bn multi-program agreement in which the partners will co-discover and co-develop innovative therapies for metabolic diseases.
From biotech experiments to billion-dollar breakthroughs, Noubar Afeyan has built a career out of turning bold ideas into transformative companies.
Alvotech and Teva have become the latest Eylea biosimilar developers to announce a settlement allowing a US launch in late 2026. However, first they must clear the hurdle of FDA approval following a recent CRL.
A new face seconded to the European Commission's medtech unit and changes to several EU rules impacting medtech
Beyond the fierce Lilly and Novo Nordisk competition in the weight-management market, other deep-pocketed firms are advancing their novel candidates and seeking a way in through dealmaking.
The pharmaceutical industry continues to experience significant shifts in sales performance, with some companies achieving remarkable growth while others face stagnation or decline.